002030 达安基因
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入400,381-25.33%1,180,89712,046,1357,664,2625,341,210
减:营业总成本454,312-18.03%1,133,4415,191,4683,600,3982,713,117
    其中:营业成本235,350-6.80%584,9293,271,5351,934,0791,594,244
               财务费用(33,782)-36.74%(74,749)(111,036)(30,813)28,644
               资产减值损失(86)-99.43%(262,754)(681,999)(19,243)(9,121)
公允价值变动收益(306,861)-163.93%435,69182,321(83,779)286,228
投资收益(29,961)-249.13%(26,247)271,184219,125150,160
    其中:对联营企业和合营企业的投资收益(45,144)-754.21%(46,101)129,360164,859110,222
营业利润(474,737)-197.06%121,6226,329,2544,125,3972,940,089
利润总额(476,016)-197.68%113,5366,318,9374,120,0812,902,866
减:所得税费用(78,370)-188.14%41,804891,378501,595452,821
净利润(397,646)-199.81%71,7325,427,5583,618,4872,450,045
减:非控股权益1,573-136.06%(32,928)15,217300955
股东净利润(399,219)-199.12%104,6605,412,3413,618,1872,449,090

市场价值指针
每股收益 (元) *-0.280-196.55%0.0753.8572.5781.745
每股派息 (元) *----0.0151.7501.1100.550
每股净资产 (元) *6.015-8.12%6.3278.0525.2384.866
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容